Metabolic & Weight
MOTS-c
MOTS-c (mitochondrial-derived peptide)
16-amino-acid mitochondrial peptide · metabolic regulator
- FDA Status
- Not FDA-approved · Investigational
- Class
- Mitochondrial-encoded peptide · novel class
- Sequence
- MRWQEMGYIFYPRKLR
- Half-life
- ~24 hours
Mechanism of action
- AMPK activation in skeletal muscle
- Improves insulin sensitivity in metabolic tissue
- Modulates folate cycle and methionine metabolism
- Mitochondrial biogenesis support
Research areas
- Insulin resistance and type 2 diabetes
- Age-related metabolic decline
- Exercise capacity and athletic performance
- Mitochondrial dysfunction syndromes
Evidence and clinical data
Discovered in 2015. Strong preclinical evidence in obesity and aging models. Phase I human trials underway. Endogenous human peptide gives it interesting safety profile.
Safety profile
As an endogenous human peptide (decreases with age), pharmacological supplementation has theoretical safety advantages. Limited human data.
Why this peptide is trending in 2026: New star of the longevity peptide world. Endogenous origin and AMPK pathway make it scientifically attractive.
Educational use only. PeptideAdvance does not sell MOTS-c, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.